Stock Markets

Daily coverage of equity markets, sectors, and major indices.

In-depth reporting on U.S. and global stock markets, including index performance, sector rotation, earnings reactions, volatility trends, and notable single-stock moves. Designed to help traders and investors understand what is driving price action across equities.

Articles

25,383 total articles

Deutsche Bank Upgrade Lifts Adecco Shares as Swiss Market Momentum Helps

Deutsche Bank Upgrade Lifts Adecco Shares as Swiss Market Momentum Helps

Adecco Group AG Class N shares rose after Deutsche Bank upgraded the staffing firm to Buy from Hold while keeping its CHF 22 price target. The upgrade, combined with a broadly supportive Swiss market and a valuation seen as attractive after a pronounced share decline, pushed the stock higher despite ongoing fragility in recruitment markets and no i…

Porsche Preferred Shares Slip After Sharp Drop in First-Half Deliveries

Porsche Preferred Shares Slip After Sharp Drop in First-Half Deliveries

Porsche AG's preferred shares declined after the automaker revealed a 16% fall in global vehicle deliveries for the first half of 2026, marking its weakest H1 in six years. The report highlighted steep regional declines, the end of certain U.S. tax incentives for electrified vehicles, and the discontinuation of combustion 718 models as drivers of t…

Raymond James Assigns Street-High $800 Target to SpaceX, Spotlighting Wide Gap in Market Views

Raymond James Assigns Street-High $800 Target to SpaceX, Spotlighting Wide Gap in Market Views

Raymond James analyst Brian Gesuale began coverage of SpaceX (SPCX) with a Strong Buy and an $800 per share target, implying about 440% upside from the stock's July 8 close of $148.30. The initiation positions SpaceX as a once-in-a-century infrastructure opportunity centered on Starship, while other analysts and market participants express a mix of…

Shares of Alnylam and BridgeBio Rally After Rival’s Late-Stage Heart Drug Misses Primary Goals

Shares of Alnylam and BridgeBio Rally After Rival’s Late-Stage Heart Drug Misses Primary Goals

Alnylam Pharmaceuticals and BridgeBio Pharma saw sharp premarket gains after an announcement that Ionis Pharmaceuticals and partner AstraZeneca’s late-stage candidate, Wainua, did not achieve its primary endpoints for reducing cardiovascular deaths and recurrent heart problems. The trial failure reduced a previously estimated $2 billion peak-sales …

Comet Shares Jump After BofA Lifts Rating and Price Target

Comet Shares Jump After BofA Lifts Rating and Price Target

Comet Holding AG rallied sharply after BofA Securities upgraded the stock from Underperform to Buy and more than doubled its price objective, citing stronger visibility into NAND memory buildout and raising revenue forecasts led by the company’s Plasma Control Technologies unit. The move fired buying interest even as broader U.S. markets were mixed…